These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 340039)

  • 1. Piperazinedione in metastatic renal carcinoma.
    Pasmantier MW; Coleman M; Kennedy BJ; Eagan R; Carolla R; Weiss R; Leone L; Silver RT
    Cancer Treat Rep; 1977 Dec; 61(9):1731-2. PubMed ID: 340039
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II evaluation of piperazinedione in metastatic breast carcinoma.
    Palmer RL; Samal BA; Vaughn CB; Tranum BL
    Cancer Treat Rep; 1977 Dec; 61(9):1711-2. PubMed ID: 340035
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II trial of piperazinedione in Hodgkin's disease, non-Hodgkin's lymphoma, and multiple myeloma: a Southwest Oncology Group study.
    Jones SE; Tucker WG; Haut A; Tranum BL; Vaughn C; Chase EM; Durie BG
    Cancer Treat Rep; 1977 Dec; 61(9):1617-21. PubMed ID: 340032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Piperazinedione in patients with advanced malignant melanoma: a Southwest Oncology Group study.
    Al-Sarraf M; Thigpen T; Groppe CW; Haut A; Padilla F
    Cancer Treat Rep; 1978 Jul; 62(7):1101-3. PubMed ID: 356973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of 4'epi-adriamycin for advanced hypernephroma.
    Benedetto P; Ahmed T; Needles B; Watson RC; Yagoda A
    Am J Clin Oncol; 1983 Oct; 6(5):553-4. PubMed ID: 6577784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of piperazinedione in metastatic sarcoma.
    Presant CA; Bartolucci AA
    Am J Clin Oncol; 1982 Apr; 5(2):185-7. PubMed ID: 7046413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of piperazinedione (NSC 135758) in the treatment of advanced or recurrent carcinoma of the ovary. A Gynecologic Oncology Group study.
    Thigpen JT; Blessing JA; Arseneau JC; Homesley HD
    Am J Clin Oncol; 1984 Jun; 7(3):261-3. PubMed ID: 6547268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I evaluation of piperazinedione in patients with advanced cancer.
    Currie V; Woodcock T; Tan C; Krakoff I; Young C
    Cancer Treat Rep; 1979 Jan; 63(1):73-6. PubMed ID: 369694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of amsacrine in metastatic renal cell carcinoma: a Cancer and Leukemia Group B study.
    Amrein PC; Coleman M; Richards F; Poulin RF; Berkowitz I; Kennedy BJ; Green M; Herschkopf R; Rafla S
    Cancer Treat Rep; 1983 Nov; 67(11):1043-4. PubMed ID: 6688967
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II evaluation of pyrazofurin in patients with advanced colorectal carcinoma.
    Carroll DS; Kemeny NE; Gralla RJ
    Cancer Treat Rep; 1979 Jan; 63(1):139-40. PubMed ID: 369686
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase II evaluation of pyrazofurin in patients with carcinoma of the lung.
    Gralla RJ; Currie VE; Wittes RE; Golbey RB; Young CW
    Cancer Treat Rep; 1978 Mar; 62(3):451-2. PubMed ID: 348315
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase II trial of piperazinedione (NCS 135758) in the treatment of advanced or recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study.
    Thigpen JT; Blessing J; Homesley HD; Adcock LL
    Am J Clin Oncol; 1983 Aug; 6(4):423-6. PubMed ID: 6688150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of acivicin in advanced breast carcinoma: a Cancer and Leukemia Group B Study.
    Booth BW; Korzun AH; Weiss RB; Ellison RR; Budman D; Khojasteh A; Wood W
    Cancer Treat Rep; 1986 Oct; 70(10):1247-8. PubMed ID: 3530455
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase II evaluation of bisantrene in patients with advanced renal cell carcinoma.
    Evans WK; Shepherd FA; Blackstein ME; Osoba D; Taylor D
    Cancer Treat Rep; 1985 Jun; 69(6):727-8. PubMed ID: 4016779
    [No Abstract]   [Full Text] [Related]  

  • 15. Increased dosage of epirubicin and mitomycin-C for the treatment of metastatic adenocarcinoma of unknown primary site.
    Polyzos A; Koulentianos E; Tzianoumis L; Sfikakis P
    J Chemother; 1989 Jul; 1(4 Suppl):1185-6. PubMed ID: 16312826
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase II study of vindesine sulfate in the therapy for advanced renal carcinoma.
    Wong PP; Yagoda A; Currie VE; Young CW
    Cancer Treat Rep; 1977 Dec; 61(9):1727-9. PubMed ID: 340038
    [No Abstract]   [Full Text] [Related]  

  • 17. Lomustine treatment of metastatic renal cell carcinoma.
    Mittelman A; Albert DJ; Murphy GP
    JAMA; 1973 Jul; 225(1):32-5. PubMed ID: 4740302
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with metastatic hypernephroma.
    Schneider RJ; Woodcock TM; Yagoda A
    Cancer Treat Rep; 1980 Jan; 64(1):183-5. PubMed ID: 6892892
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II study of nafoxidine in the therapy for advanced renal carcinoma.
    Feun LG; Drelichman A; Singhakowinta A; Vaitkevicius VK; Oishi N
    Cancer Treat Rep; 1979 Jan; 63(1):149-50. PubMed ID: 369688
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase II trial of razoxane in the management of recurrent adenocarcinoma of the ovary: a Gynecologic Oncology Group study.
    Conroy JF; Blessing JA; Kessinger A; Homesley HD
    Cancer Treat Rep; 1984 Feb; 68(2):439-40. PubMed ID: 6697335
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.